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Sitta Sittampalam: Welcome to this roundtable discussion.
I am a senior scientist and senior advisor to the director of
the National Center for Advancing Translational Sciences
(NCATS) at the National Institutes of Health (NIH). Previously,
I was a faculty member at the University of Kansas Medical
Center for 4 years, where I was doing research on circulating
tumor cells and their relation to cancer stem cells.
Before that, I was at Eli Lilly & Company for almost
24 years, where I held a variety of different positions, ending
up as head of the lead optimization and screening lab at Lilly. I
started a program in stem cell-based screening and became
very interested in 3D cocultures and culturing of tissues.
Richard Eglen: I am the general manager at Corning Life
Sciences. My background has been in drug discovery, in
which I worked for 20 years at Roche, managing both the
neuroscience drug discovery group and some of the high-
throughput screening (HTS) activities. I then moved into
businesses that were developing technologies for screening
and for imaging. I worked for companies such as DiscoveRx
and PerkinElmer, and now Corning Life Sciences.
Throughout that time, an emerging theme of my work has
been cell-based assays, and particularly those that are used
in HTS; more recently, the emphasis has been on primary
cells and cells that are used in different sorts of cell culture,
including 3D.
Jason Maynes: I am at the Hospital for Sick Children in Tor-
onto, Canada. Clinically, I am a pediatric anesthesiologist and
my doctorate is in physics. My research involves drug design,
drug screening, and devising new HTS models, specifically
around heart failure and cardiac disease, ensuring translation
to patient care.
Kenneth Olden: My research has been in the area of cancer,
and specifically development of antimetastatic agents. For
several years, I was pharma director at the National Institute
for Environmental Health Sciences at the NIH, and there we
were very interested in developing toxicogenomic approaches
to improve drug development and toxicity testing. I am now
director of the National Center for Environmental Assessment
at the Environmental Protection Agency.
Laura Schrader: I am president and CEO of 3D Biomatrix, and
we make 3D hanging drop cell culture well plates in 96- and
384-well formats.
I joined the company just over 4 years ago to launch
this technology from the University of Michigan and bring
it to market. We have been very active on the 3D cell cul-
ture front working with researchers that focus on cancer,
toxicity testing, and stem cell research in the drug discovery
world, and also working with automation companies to in-
tegrate those technologies with 3D cell culture. Previously,
I was a medical device consultant and worked with a lot
of different equipment manufacturers in the medical device
space.
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Todd Shelper: I am a research fellow working in Prof. Avery’s
Discovery Biology lab at Griffith University in Brisbane,
Australia. Our lab is primarily an HTS drug discovery lab,
and recently we have been doing a lot of work with 3D cell
cultures and trying to introduce this technology into our HTS
campaigns.
Stephen Ferguson: I am a scientist with the National Tox-
icology Program at the NIEHS. My primary role is to incor-
porate more physiologically relevant in vitro models (in both
2D and 3D configurations) into our Tox21 Program to eval-
uate and, if possible, predict human responses to chemical
exposure. Formerly, I led the ADME/tox R&D program at Life
Technologies, where we focused on the development of pri-
mary liver cell models, HepaRG cell models, drug metabolism,
drug–drug interaction, and in vitro toxicology research.
Marc Ferrer: I work at NCATS, NIH, and my career of 15 years
has mostly been in HTS. I spent 10 years at an HTS site at
Merck Research Laboratories in North Wales, and then did
small molecule screening. In the last 5 years, I have been at
NCATS doing HTS development and small molecule screen-
ing. Here we have developed an interest in 3D models, mul-
ticell types of models, and use of stem cells for drug
development primarily.
Sitta Sittampalam: I would like to begin our discussion with
your impressions on the general usage of 3D cultures, as
opposed to 2D in industry and academia, and various other
settings in which you work.
Marc Ferrer: Speaking for those of us at NCATS, our 3D work
is, at this moment, very investigational. We do not use it for
routine screening yet, and we are focusing mostly on tumor
and cancer models. We have spent the last 2–3 years learning
how to generate spheroid organoid cultures, trying to char-
acterize them as much as we can, not only pharmacologically
using a set of control compounds, but also morphologically in
a mixed type of validation, and investigating which cells use
spheroids and which do not, and why.
I would also like to point out that not all 3D models are
spheroid models. We also had a project that involved a 3D
layer type of model for studying cell adhesion in cancer that
we were able to miniaturize to a 1536 HTS format for large-
scale screening. So 3D models are not necessarily only orga-
noid spheroid types of models, but could also be layers, sort of
bioprinting types of models as well.
Richard Eglen: From our perspective, as we develop tech-
nologies in this area, and from the kind of laboratories
we interface with, both in pharma and academia, the majority
of HTS assays are probably still undertaken in 2D. However,
we are seeing a fairly rapid acceleration in terms of assays
being done in 3D, particularly in the area of oncology
screening.
I think if you could broaden the view of 3D cell culture to
include the use of extracellular matrices, as well as synthetic
polymers and spheroids, then the usage would be greater.
We have also seen several academic labs that are excited
about this area because of the ability to do cellular assays in
patient-specific culture systems. They are starting to see dif-
ferential effects of compounds depending on the sourcing of
the cells from patients. Taken together, I would say it is cer-
tainly increasing, and it is making rapid inroads, but it is
nowhere near as widespread as 2D culture.
Sitta Sittampalam: Would you say it has advanced more
rapidly in the last 3–4 years?
Richard Eglen: Yes, I would certainly say that the field has
grown exponentially. From 2014 to 2019, the use of 3D cul-
ture is projected to triple, if not quadruple, based on industry
estimates.
Kenneth Olden:My impression is that 3D culture models offer
considerable promise, although I have not personally worked
with them. The issue is, ‘‘Are they biologically relevant?’’ I am
confident that they are going to have broad applications in
drug development and toxicity testing. A couple of things still
need to be worked out, such as scalability; they do not yet
have the capacity to be put on high-throughput platforms.
Another concern is the cost of developing these 3D models
versus the cost to do the studies in animal models.
Sitta Sittampalam: Those are definitely important concerns,
the accessibility, the cost, and the scalability. Also, something
we are going to discuss a bit later is the validity of 3D models
and how well they represent disease pathology.
Laura Schrader: Regarding Ken’s comments about scalability
and use on a HTS platform, I think that is one of the chal-
lenges—and opportunities—that relate to the many different
technologies emerging on the market right now for 3D; they
all have different places along the process to fit in.
But there are products—ours being one of them—that were
built specifically for creating 3D cell culture spheroids and
cocultures that can be used in HTS applications, with 96- and
384-well plates. So they do exist, and the world needs to know
about this. There has to be a plan to set up the right experi-
ments using the right 3D path as they go forward through their
process. What are the endpoints they want to answer, and
those sorts of things?
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These types of products do exist, and they do not necessarily
have to cost a lot. There are different levels of products
available to achieve 3D with controllability. On the assay
front, we have seen the market develop, and I would say that
the majority of our scientists use assays on the spheroids that
they grow on our plates and agree that this market is growing
rather rapidly, and has grown since we launched over 4 years
ago. If assays work in 2D, they can be optimized and tested for
repeatability to achieve things in 3D.
Stephen Ferguson: Adding to what Dr. Olden said, I abso-
lutely agree that one of themain drivers for moving toward 3D
is an ability or a hope that these models will improve the
physiological relevance, and support a broader biological
space that better mimics tissue/organ function.
We are particularly interested in evaluating these models,
developing them, and assessing the extent of ‘‘normal’’ bi-
ology modeled. For example, in our case, we are interested in
models that, in the near term, improve the physiological rel-
evance of in vitro liver models to support xenobiotic metab-
olism to evaluate chemicals and mechanisms associated with
metabolically activated toxicity.
I also want to comment on the idea of cost. The general
dogma is that 3D is going to be more expensive than 2D. I think
that can be true, especially in a situation in which you are
looking at cancer cells that oftentimes grow and proliferate
without additional costs (except for themedia/flasks). However,
in my field, employing primary liver cells or HepaRG cells,
these are quite expensive. Therefore, the opportunity to mini-
aturize with 3D (e.g., spheroid configurations) could actually
improve their compatibility with and costs for screening.
Sitta Sittampalam: That is an interesting point because the
primary cells are so expensive.
Stephen Ferguson: Yes.
Sitta Sittampalam: What Steve just said about the physio-
logical relevance takes us directly into the second question
about the predictive value of this compared to 2D versus
in vivo. It is a crucial question for in vivo efficacy and toxicity
and is one of the biggest technical challenges, which is one of
the other main topics we are going to discuss.
Jason Maynes: I think I am the only physician on the panel,
and I really have significant doubts as to the physiological
relevance of these in the near term. I think you have to con-
sider this in terms of two groups: oncology and then every-
thing else.
Whereas the usefulness of these 3D models has been shown
mostly in oncology-type assays, which makes sense because
most cancers do not actually have a strong anatomy per se,
and the toxicology or the drug efficacy in certain cancers is
often associated with whether the drug can penetrate the
cancer. So it makes sense then to look at the many sorts of
disorganized spheroids or organoids, or even a monolayer
with an endothelial cell underneath. But in terms of a more
organized tissue and discovering therapies for preventive
medicine or organ function, I do not think this is something
that is going to happen in the next 10 years. It may be ac-
celerating, but in terms of getting it to a point where it is used
in drug screening, that is pretty tough.
We have collaborations with engineers where we are trying
to develop a higher throughput way to measure cardiomyo-
cyte contraction on a nanotube. In terms of scar formation or
cardiomyocytes or any contractile cell, you can grow them on
a 3D wire or tube and measure contractions.
But even with those examples, you are not really mimicking
what the organ is doing. There is minimal cell–cell coopera-
tion, and you are ignoring the different types of tissues that
may be involved, or different types of cells that exist within a
single tissue. So I have real doubts as to the short- to medium-
term ability of any of these approaches to mimic true physio-
logy and make a difference.
I think it is an important thing to evaluate, and certainly
there is a lot of movement toward it. But I just do not see the
relevance of it right now outside of oncology.
Sitta Sittampalam: When you say cell-to-cell contact, are you
talking about extracellular matrices and the whole tissue
context, and whether this can be generated outside the oncology
platform in a relevant way?
Jason Maynes: Yes, in a way that adds something that we do
not already have the ability to mimic in some other way. If you
are going to develop a new technology, there certainly has to
be a reason to develop it.
Sitta Sittampalam: Todd, do you have an opinion on whether
3D culture is any better than 2D and whether it is any more
predictive of what occurs on the in vivo side, even outside
the area of oncology?
Todd Shelper:Most of our screening, our routine screening, is
still done using monolayer culture methods. But over the last
4–5 years, we have definitely been doing most of our assay
development in 3D cell culture with cancer cell lines—either
basic mono- or coculture 3D formation using Matrigel. Some
of the technical challenges are miniaturization, trying to bring
the costs down by moving to 384- and 1536-well plates, and a
lot of work has gone into characterizing these types of assays.
Once you get down to the 1536 level, the costs are actually
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significantly reduced and are comparable to the monolayer
assays.
Sitta Sittampalam:Are you also doing 3D culture in 1536-well
plates?
Todd Shelper: Yes, absolutely. With the cost of Matrigel,
which we use for our 3D culture generation, at the 384-well
level, the cost per data point or the cost per compound tested is
significantly higher.
Stephen Ferguson: I think that the general concept that these
sorts of 3D models will be able to fully mimic tissues and
organs is probably, as previously stated, quite a long way
away from being a reality. However, we do know that the 2D
models can predict more apical endpoints related to drug
metabolism and drug–drug interaction potential. The early
evidence indicates that 3D and flow models more closely re-
semble in vivo function. For example, numerous reports have
shown improved functionality with 3D cultures and flow
cultures for xenobiotic metabolism competence more closely
mimicking in vivo levels.
So I think that some properties are definitely improved by
using these models. However, mimicking comprehensive tis-
sue or organ function with these systems is definitely some
time away.
Marc Ferrer: I would like to emphasize what Jason said about
oncology versus nononcology. For oncology we can generate
spheroids in 384 wells quite well now, and quite inexpen-
sively. We can use the typical kinds of cell data Glo [CellTiter-
Glo; Promega] types of readouts and measure the size of the
spheroids quite well.
What I have noticed is that when we start screening com-
pounds we see differences between 2D and 3D culture systems.
But we do not really understand why, because we do not know
whether the compound is not penetrating or whether there are
changes in the signaling or the metabolism when you go into
3D, and whether that could be responsible. Are these differ-
ences what really happens in vivo, and is that why you lose the
efficacy of the compound?
So that is one aspect we are focusing on, understanding the
differences, why we see differences for 2D versus 3D. In-
vestigating the biology of these spheres is one of our priorities.
One of the main technical challenges involves how you
visualize these spheroids: with confocal, with nonconfocal,
what penetration you get, what size spheres do you need to
have relevance?
These are all questions that we still have and need to in-
vestigate before putting this into large-scale screening, be-
cause these factors will impact the predictability. You do not
want to be using a system for screening that is not going to be
predictable. So how much do we need in a sphere to make it
predictable? That is what we are trying to answer.
Richard Eglen: In terms of the use of 3D culture for metabolic
liability testing, I think emerging data suggest that, in terms of
compound screening and compound optimization in the liver
field, the physiological relevance is improving. So this may be
one area in which 3D cultures will be useful in the nearer term.
There is actually very little reported evidence on real dif-
ferences in pharmacology when you compare 2D and 3D
culture, although by the nature of 3D culture you get different
wrapped assemblies of surface receptors. Consequently, you
can get homodimerization versus heterodimerization, partic-
ularly in some cancer targets. And that will give different
pharmacologies.
I also want to mention that in terms of providing disease
models, there are now data being published showing that 3D
cultures may make good models for Alzheimer’s disease. So it
may be that the field is starting to broaden in applicability
beyond the oncology area. In fact, there is one group, as re-
ported, that is now using 3D neuronal cultures to look at tau
phosphorylation and inhibitors of that process.
Therefore, while it may be early days, my feeling is that it is
on its way and is broadening beyond the bridgehead, if you
like, of oncology screening.
Sitta Sittampalam: Okay, that is good to know. I think I
remember somebody publishing something on 3D cultures/
neuronal cultures for Alzheimer’s disease. I do not recall
whether they are spheres, but I do remember something on
the news.
Laura, based on your experience with customers, what
technical challenges and issues related to validity and pre-
dictive capabilities are they looking at?
Laura Schrader: When I look at this question of whether 3D
cell cultures are better predictors than what they are using
now in large-scale 2D screens, a lot of our customers are still
in the exploratory stages. We have large pharma customers
that have said that it takes a little more time to set up 3D
cultures, but you get much more robust and specific data that
reveal a lot more information that may be missed in 2D be-
cause of the quantity and the quality of the data obtained from
3D cultures.
3D culture is never going to be the same as a human, but the
whole goal is to make preclinical research as physiologically
relevant as early as possible. At first we thought it would
narrow down the number of hits in secondary screening. We
learned it also makes the hits stand out more because of the
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additional data. So those are the targets that are beginning to
move forward, and the companies are moving them forward
with greater confidence, just based on the greater depth of
data attained.
While it may still be a few years before the use of 3D cul-
tures in HTS becomes common practice, in terms of 3D being
more predictable than 2D, we are getting good indications that
this is the case.
Sitta Sittampalam: Do you see it being applied mostly in
oncology?
Laura Schrader: It is largely oncology, yes, and toxicology. It
is also growing more and more in stem cell differentiation.
Because there is no plastic for the stem cells to adhere to, they
like that.
Kenneth Olden: With the fact that it is mostly applied in
oncology now, is that simply a reflection of the commu-
nity’s interest in developing these models for cancer sys-
tems? Diseases, all of them, are organ-specific, and these
3D cultures maintain differentiated states. So I do not see
why they would not have relevance to other diseases as
well. And one could certainly monitor the biomarkers to
make sure that the differentiated state is either maintained
or induced.
Marc Ferrer: I think for other diseases it is technically more
challenging. I think it is easier to make a spheroid; you just
need a round-bottomed ULA [ultra-low attachment] plate. But
for other diseases, the geometry of the culture and how the
cells are organized is more critical. For that you go into sort of
the bioprinting world, and it is very early, technically chal-
lenging days for that, but is another direction for 3D cultures
in the future. Not all 3D cultures are spheres.
Richard Eglen: Just to pick up on what Laura mentioned
about the increasing use of stem cells. They appear to grow
better and differentiate best in a 3D environment. If you
think about the increasing adoption of stem cells in drug
discovery, then maybe its adoption is coinciding with the
increasing adoption of 3D culture as well. As those two
technologies come together in lead optimization and disease
modeling, they probably will ultimately find their way into
HTS as well.
Sitta Sittampalam: Before I go on to the next questions, I want
to ask any or all of you whether you have looked at penetration
of molecules, small molecules, into 3D cultures in a systematic
way. Promega, for example, is putting out assays for 3D cul-
tures that have very special types of Glo detergents so the dyes
can penetrate.
This is an issue on the detection end of the business. I saw an
article in Cell recently in which the researchers incubated so-
called tumor organoids with a drug for 7 days. Have any of you
studied drug penetration and diffusion into these tumors? That
would be one of the big technical challenges.
Laura Schrader: From a commercial standpoint and based on
what we hear from our customers, being able to control the
size of the spheroids is an important factor in being able to
read inside of them. The technology exists to be able to read
inside of them with high-content analysis, but we have cus-
tomers that are able to create spheroids that are 200 microns,
or grow them even bigger to get a necrotic core on purpose.
And they use a lot of different kinds of assays. CellTiter Glo
works, and they improved it for 3D, as does Alamar Blue.
There are a lot of existing assays that have been optimized and
tested for spheroid reading and they work as well.
Stephen Ferguson: I would say that, in general, even 2D
cultures have been underserved with regard to understanding
the amount of compound accumulating inside the cells. But
for 3D cultures, many factors, including increased surface
area, ratios of compound to cellular biomass, and other fac-
tors, may play important roles in our ability to relate in vitro
responses to in vivo. Our lab is interested in exploring these
approaches to add context to in vitro toxicology data.
In the near term we have begun looking at high-content
imaging approaches such as cholyl-lysyl-fluorescein (CLF),
which actually is reported to be a BSEP [bile salt export pump]
substrate in liver, an efflux transporter on the canalicular
membrane. What we see is that the spheroids take up the CLF
and transport it to canalicular networks that formed over time
in culture within the spheroids. I think there may be other
articles in the last few years that have shown similar data.
I believe there is sufficient evidence to show that high-
quality 2D and 3D liver models are not cholestatic, as
some have suggested, but actually have a form of cellular
circulation including uptake transport and biliary efflux
into canalicular pockets. However, the kinetics, resulting
accumulations/disposition, and dependence on size and
media composition need to be further explored with 3D
models.
Sitta Sittampalam: How big are your 3D structures?
Stephen Ferguson:We have used different sizes, but the ones
that we are most intrigued by so far actually are quite small.
They are only 1000 cells, so probably 100–150 microns.
Todd Shelper:We have performed studies looking at standard
chemotherapy agents and penetration through some of our
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pancreatic cancer and breast cancer 3D cultures. Looking at
doxorubicin with high-content imaging, you can see the
levels of penetration through different-sized spheroids.
Sitta Sittampalam: How big were the spheroids, the biggest?
Todd Shelper: They ranged from 100 to 500 microns, but with
confocal microscopy you start to reach the limits of what you
can actually penetrate through with the dyes and the lasers we
are using.
Marc Ferrer: Did you see a difference in the types of cancer?
We have seen that some types of cancer form very tight
spheres, whereas others do not form as tight spheres, re-
gardless of how much ECM they secrete. That is something we
are exploring further because you might have penetration for
one cell type but not for the other ones.
Todd Shelper:With the tightly packed 3D structures that have
a lot of cell-to-cell contact, we saw fairly similar penetration
levels as those of the more loosely packed cell types. It seemed
to be independent of where the cells originated from.
Richard Eglen: Several authors have looked at the pharma-
cology of compounds in hepatocytes cultured in 2D versus 3D,
and here you can see a frame shift to the right in 3D, which
probably more accurately reflects the potency of compounds.
That may be a penetration issue, but it may also be that the
cells are performing as they do in vivo.
I would also mention cell migration assays, and the fact that
they can be done with these models as well. As you start to
image the cells migrating into the organoid or the spheroid,
then you can get really appropriate pharmacology compared
to what occurs in vivo. Those are surrogate measures, and not
exact measures of compound penetration, but there are
pharmacological outcomes that can be measured.
Sitta Sittampalam: Okay, thank you. I am now going to move
on and talk about 3D multicellular cocultures—multiple cell
types in a 3D structure versus organoids, which are essentially
miniature organs.
In the same article in Cell that I mentioned earlier, the re-
searchers were taking human biopsies from colon cancer and
from normal colon about 10 cm away from the same patient,
and they were growing the samples and calling it an orga-
noid and doing drug testing.
The two questions I would like us to discuss, which are
related in many ways, are as follows: Are validated multicel-
lular 3D cocultures representing disease pathology readily
available? And is growing 3D organoids from diseased tissue a
superior approach, compared to 3D cocultures developed from
cell lines or primary cells?
Laura Schrader: I can discuss this from a more commercial
standpoint and some of the current ideas around 3D cell
culture. First, cocultures are easier to attain and use than
are organoids. But the main point is that they are both
relevant.
Organoids are probably more costly, especially if they are
coming directly from a human biopsy. They are comprised of
more costly and valuable cells, and are very intricate, valuable
technology. But this is a good example of how there is not one
‘‘silver bullet’’ 3D platform.
Various 3D methods can help you accomplish different
results at different stages. So, if we are working to discover
therapies in 3D human tissue, then research should start
as early as possible using more simple 3D platforms, like
our Hanging Drop Plates, then moving those promising
targets forward for greater scrutiny in more sophisticated
3D environments like organoids. All of this, of course,
precedes moving into more extensive and expensive animal
studies.
The exploratory work some of our customers in biotech and
pharma companies are doing is focused on trying to figure out
the best path to achieve physiological relevance as early as
possible. I think all of the 3D technologies have a certain place,
depending on the type of research, and organoids are certainly
sophisticated tools to use.
Sitta Sittampalam: Jason, what do you think? You had some
concerns about how long this is all going to take?
Jason Maynes: I think a lot of this depends on what disease
you want to look at and what system you want to model. As
Laura said, there is not going to be one solution.
I do worry a little bit about the comment that the 3D cul-
tures give better results. I think they currently give different
results compared with 2D cultures, but is that better or just
different? And that is a challenge you need to be aware of,
because you may work with organoids or with a coculture and
you may get two different results. There is no evidence that
one is right and one is wrong. They are just different.
Marc Ferrer: I agree, Jason.
Jason Maynes: Until you go back and validate in an in vivo
system and determine which worked and which did not, then
you cannot be sure that either of them is relevant. They are just
different. The closer you get to the organ, the better, but you
are limited by thickness and nutrient flow and other factors; at
this particular time, the main issue is validity.
Whichever of those two methods ends up giving you the
better model of your in vivo system, then that is the right
answer to pick. But you have to validate it. You cannot say it is
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better just because it gives different results. What it will take is
a few of these systems to be developed, utilized, discovered,
and validated before we will really know which of them
should be used more broadly.
Sitta Sittampalam: Yes, I agree.
Marc Ferrer: I agree with Jason, and I think one of the things
that is hard to find is the sort of positive indicators—the
compounds or the treatments that you can use to validate
these models. Ideally, those would be compounds that work in
the clinic, or maybe they did not work in the clinic but they
worked in 2D.
What profile of compound do you use to validate and
benchmark these models?What sort of compound will you use
to say, ‘‘Yeah, now this is a predictive model.’’ You have to
have the clinical data or in vivo data to use as a benchmark,
and sometimes getting that data is not easy.
Sitta Sittampalam: It is not easy, but then you can take your
existing drugs and try to validate them and go into an in vivo
model and try to see whether all of them correlate.
Marc Ferrer: But you have to go into the clinic and say, ‘‘Okay,
this compound worked in a xenograft, but failed in the clinic,’’
or ‘‘This compound, where did it fail, why did it fail?,’’ or ‘‘This
one worked, and why did it work?’’ And we have compounds
that actually work in the clinic, but did not work in a 2D
culture. Can we use those to validate or develop a 3D culture,
and will that 3D culture be predictive?
Stephen Ferguson: I agree with what Jason said as well on a
lot of fronts. We know that as you remove primary hepa-
tocytes from the tissue they can rapidly dedifferentiate in
terms of xenobiotic metabolism competence. When you
put these cells in 3D and/or dynamic flow contexts, they
often far exceed their 2D thresholds of metabolic compe-
tence and regain levels more comparable to their initial
in vivo levels.
The way we view it, the closer an in vitro liver model can
mimic the metabolic competence found in cells directly de-
rived from liver, the better chance we are going to have to
model normal liver metabolism.
Sitta Sittampalam: Do any of you think that this is in the
context of tumor 3D versus other organs? Are there some or-
gans that are much more difficult than other organs? I think,
Steve, the liver is one of the organs that some companies are
going after right now to make 3D tissue.
Stephen Ferguson: At this point my perception is that for
tissues with more independent functionality, they are going to
have a better chance. However, when you try to model organs
that are more interactively dependent on other organs/
systems for ‘‘normal’’ function, it may limit our ability to ef-
fectively model these organs/tissues without integrating these
systems in some sort of systemic flow.
Richard Eglen: To add to what Steve was saying, you can
make organoids from a range of tissues: intestinal, retinal, all
the way through to even neuronal tissue. But they require the
characteristics of the tissue, not just colocalization of the cells,
but also flow, removal of waste products, delivery of meta-
bolic products, etc. That is likely the reason why the liver
physiology has advanced.
Sitta Sittampalam: In that context, Richard, most of you
probably know about the tissue chip program that NCAT funds
at multiple sites. DARPA [Defense Advanced Research Pro-
jects Agency], FDA [Food and Drug Administration], and the
NIH also fund this program, in which they are going to put
various 3D organs onto a tissue chip and integrate them as a
human-on-a-chip. Essentially, it is a 10- or 15-year project, if
it can be done at all. But it is really a moon shot. I just wanted
to mention that in the context of this discussion.
Before we conclude, do any of you have questions for each
other?
Kenneth Olden: There is one point I would like to bring up
and that is getting regulatory bodies to adopt these systems.
What effort has been made to inform regulatory bodies of
the pros and cons and strengths and weaknesses of these
systems as they are being developed? I think that is going
to be very important. We do not want to develop a tech-
nology and have regulatory bodies be reluctant or slow in
accepting them.
Sitta Sittampalam: I think that is a very, very important point.
Kenneth Olden: When we developed the toxicogenomic
center in NIEHS, we got the National Academy of Sciences to
develop a roundtable and bring industry and environmental
groups and regulatory bodies together to discuss the science
so they would understand it and there would not be rejections
out of ignorance..
Laura Schrader: There is also the Center for Responsible
Science, or CRS. They are a group that focuses on streamlining
drug and device development to get safer and more effective
products out to patients faster in a less costly manner. I know
that they are working on some ways to approach the FDA to
include emerging technologies as a part of the regulations,
including for preclinical stages. This is more for validation. So
I think there is such an effort underway.
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JasonMaynes: I think the FDA is certainly open to technology
like this. We interface with the CIPA [Comprehensive In Vitro
Proarrhythmia Assay] Initiative, which is the cardiac safety
committee at the FDA, and HESI [Health and Environmental
Sciences Institute], and so forth. They are certainly willing to
look at new models for preclinical cardiac toxicity, and the
FDA has shown an ability to apply that evidence for phase I,
and to be open to looking at other modalities.
Richard Eglen:Marc mentioned bioprinting a couple of times,
and I was wondering what people on the line think of that and
how close the field is to being used in these kinds of areas?
Stephen Ferguson: We have a small collaboration going on
with a bioprinting group. I think there is a lot of excitement
around the way that they can essentially print vasculature.
The challenge that I see now is combining cells to more closely
mimic tissue architecture (e.g., liver lobular structures). This
should drive these models toward more physiologically rele-
vant function.
Jason Maynes: We have a couple of collaborations with
biomedical engineering groups in which we do both Inkjet,
spin printing, and also, as I said, the biowires, where we spit
out the cells onto wires. I agree that the architecture is not
there yet, but at least we can generate defined layers of cells
that seem to interact with each other and maintain that ar-
chitecture. So the technology is getting there, but it’s a long
way from high throughput.
Richard Eglen: Yes, I agree.
Sitta Sittampalam: Marc and I are working on bioprinting as
well. We are focusing on retina and skin with the National Eye
Institute and also with the National Institute of Arthritis and
Musculoskeletal and Skin Diseases.
These structures have very special architecture, very special
layers, and we are experimenting with bioprinting those
structures. Although the technology is very early right now, in
my opinion, it is worth looking at.
Laura Schrader: There is a question I would like to throw out
to this dynamic group. As we have been going through this
over the last few years, there have been questions about what
it is going to take to make researchers think that 3D works.
Jason touched on the fact that you absolutely have to have a
model and validate that it has the expressions that are present
in vivo. Does this group have any comments or thoughts about
what it will take for 3D to become the norm?
Stephen Ferguson: I think successful systems will need to
effectively model an important subset of ‘‘normal’’ biology to
warrant adoption. If you are modeling some bit of normal
biology that is relevant, then I think that will have a stronger
opportunity for adoption with these emerging in vitromodels.
Todd Shelper: I think if you could find a hit compound or a
lead compound that was identified in 3D but not found in a 2D
system and thenmade it all the way through the drug discovery
pipeline, that might provide strong evidence of its value.
Sitta Sittampalam: I agree. That is the same kind of challenge
HTS had in the early days. So it is very similar.
I would like to thank you all very much for participating in
this discussion. In summary, I think we agree that this field is
still exploratory, but there is a rapid awareness in the aca-
demic, pharmaceutical, and biotech worlds of 3D technology.
Cost and accessibility are things that people have to think
about. Another important point that was brought out is that 3D
cultures are currently much more prevalent in the oncology
world and other areas are maybe a little bit behind because of
the technical challenges in producing other 3D tissues.
The validity of the system has to be still proven in multiple
ways—2D versus 3D versus in vivo—and the proof of validity is
physiological relevance. How good is the model physiologi-
cally, how well can it mimic what is happening in vivo,
whether it is a 3D coculture or a 3D organoid, and howwell can
we use that data?
Then there are obviously analytical challenges in measuring
some of these activities in 3D constructs. We also discussed the
use of bioprinting, the use of stem cells to enhance the for-
mation of 3D cultures, and about cocultures versus organoids.
Another important point was whether a different result seen in
3D versus 2D is a better result, or just a different result. I think
the jury is still out on that one. Finally, many of you pointed out
that the regulatory bodies need to adapt this, and there are
some efforts going on through the Center for Responsible Sci-
ence and some discussions with the FDA, specifically in the
cardiac preclinical arena.
In terms of costs, eventually the costs of these systems will
probably come down. Primary cells are still quite expensive and
are much more difficult to use.
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